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Abstract 
Background: Lung cancer is the leading cause of cancer mortality in the United States. Non-small cell lung cancer 
accounts for 85% of all lung cancers for which adenocarcinoma is the most common histological type. Management 
of lung cancer is hindered by high false-positive rates due to difficulty resolving between benign and malignant 
tumors. Better molecular analysis comparing malignant and non-malignant tissues will provide important evidence of 
the underlying biology contributing to tumorigenesis.
Methods: We utilized a proteomics approach to analyze 38 malignant and non-malignant paired tissue samples 
obtained from current or former smokers with early stage (Stage IA/IB) lung adenocarcinoma. Statistical mixed effects 
modeling and orthogonal partial least squares discriminant analysis were used to identify key cancer-associated 
perturbations in the adenocarcinoma proteome. Identified proteins were subsequently assessed against clinicopatho-
logical variables.
Results: Top cancer-associated protein alterations were characterized by: (1) elevations in APEX1, HYOU1 and PDIA4, 
indicative of increased DNA repair machinery and heightened anti-oxidant defense mechanisms; (2) increased LRP-
PRC, STOML2, COPG1 and EPRS, suggesting altered tumor metabolism and inflammation; (3) reductions in SPTB, 
SPTA1 and ANK1 implying dysregulation of membrane integrity; and (4) decreased SLCA41 suggesting altered pH 
regulation. Increased protein levels of HYOU1, EPRS and LASP1 in NSCLC adenocarcinoma was independently vali-
dated by tissue microarray immunohistochemistry. Immunohistochemistry for HYOU1 and EPRS indicated AUCs of 
0.952 and 0.841, respectively, for classifying tissue as malignant. Increased LASP1 correlated with poor overall survival 
(HR 3.66 per unit increase; CI 1.37–9.78; p = 0.01).
Conclusion: These results reveal distinct proteomic changes associated with early stage lung adenocarcinoma that 
may be useful prognostic indicators and therapeutic targets.
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Background
Lung cancer is a leading cause of cancer mortality in both 
men and women in the United States [1–3]. Non-small 
cell lung cancer (NSCLC) accounts for 85% of all lung can-
cer cases for which NSCLC adenocarcinoma is the most 
common histological type [4]. While use of low dose com-
puterized tomography (LDCT) for screening of persons at 
high risk for lung cancer can reduce cancer mortality, it is 
plagued by high false positive rates (96%) [5] because it is 
unable to adequately distinguish indolent (benign) solid pul-
monary nodules (SPNs) from malignant SPNs. Increased 
knowledge of the molecular perturbations caused by tumo-
rigenesis is needed to better understand the underlying biol-
ogy, as well as potentially assisting with diagnosis, prognosis 
and identification of additional treatment targets.
Improved ‘Omic’ based analytical methods (e.g. 
genomics, transcriptomics, proteomics and metabo-
lomics) gives us greater ability to monitor all biochemical 
processes associated with tumorigenesis with increas-
ingly smaller amounts of difficult-to-obtain clinical speci-
mens. Proteomics is particularly well suited to identify 
the underlying biology of lung cancer. Protein expres-
sion is the ultimate product of gene expression and is 
controlled through transcriptional, translational and 
post-translational regulations, all of which are highly 
dependent on cellular signaling [6]. Unlike genomics 
(DNA and RNA), proteomic analysis is more complex 
due to the presence of sequence variations, isoforms, and 
post-translational modifications, yielding multiple pro-
tein isoforms of the same gene Proteomics can uncover 
powerful links between gene function and tumorigenesis, 
help discover clinically useful diagnostic and prognostic 
biomarkers for early stage NSCLC adenocarcinoma [7–
9]. In the current study, a shotgun tandem liquid chroma-
tography mass spectrometry (LC–MS/MS) approach was 
used to characterize proteomic differences between 38 
matched malignant and non-malignant lung tissue pairs 
obtained from current or former smokers with early stage 
(IA-IB) NSLCL adenocarcinoma. Statistical analysis and 
multivariate modeling were used to identify the top 10% 
of all measured protein changes that best distinguished 
adenocarcinoma from control tissues. Identified pro-
teins were additionally evaluated against clinicopatho-
logical variables. Three top candidate proteins, EPRS, 
HYOU1 and LASP1 from the discovery study were inde-
pendently validated with a tissue microarray containing 
40 pairs of malignant and non-malignant tissues from 
patients with early stage NSCLC adenocarcinoma. We 
hypothesize that identification of cancer induced cellular 
and tissue level protein changes will provide candidate 
tissue-specific prognostic markers for early stage adeno-
carcinoma that may eventually be used to better distin-
guish adenocarcinoma from benign tissues, help identify 
potential therapeutic targets for treatment of lung can-
cer and, importantly, improve our understanding of the 
mechanism(s) leading to lung cancer.
Methods
Sample acquisition
De-identified malignant and adjacent non-malignant lung 
tissue samples were harvested in the operating room from 
patients having resection or lobectomy for non-small cell 
lung cancer, none of whom received preoperative treat-
ment. The matching control lung tissue was always taken 
from areas 8–10  cm removed from the cancer bed. All 
procedures were approved by institutional IRB protocols 
(NYU) with patient consent. Tissues were immediately 
frozen in liquid nitrogen and stored at −80 °C. Specimens 
were annotated for age, gender, race, diagnosis (includ-
ing stage), smoking status and pack-years. Criteria used 
to select patient cases were: (a) current or former smok-
ers; (b) diagnosis of NSCLC adenocarcinoma; (c) early 
stage IA or IB; and (d) understood and signed the IRB 
consent form. Of the 38 samples analyzed in the study, 
14 (36.8%) were from patients that had recurrent cancer 
within 5 years. The inclusion of these 14 subjects was to 
identify potential prognostic biomarkers of early stage 
adenocarcinoma.
Proteomic analysis
Preparation of samples for proteomic analysis
Preparation of tissues and N-glycan release followed by 
ethanol precipitation of tissue proteins has been previ-
ously described in Ruhaak et al. [10].
Trypsin digestion of samples
Protein pellets were solubilized in 100 µL of AMBIC (6 M 
urea, 50  mM ammonium bicarbonate) with dithiothrei-
tol added (final concentration 5  mM) and incubated at 
37 °C for 30 min. Iodoacetamide (IAA) was added (final 
concentration 15  mM), incubated for 30  min (RT) and 
DTT added to quench the IAA reaction. Lys-C/trypsin 
(Promega) was next added (1:25 enzyme:protein ratio), 
samples incubated (4  h at 37  °C) after which the urea 
concentration was lowered (<1  M) and samples further 
digested (overnight, 37  °C). Samples were desalted (C18 
Macro Spin columns, Nest Group) and lyophilized.
LC–MS/MS analysis
Reconstituted samples were randomized into 8 blocks of 4 
normal and 4 tumor samples. Triplicate LC–MS/MS analy-
ses were acquired for each sample. LC separation was done 
on a Waters Nano Acquity UHPLC (Waters Corporation) 
with a Proxeon nanospray source. Mass spectra was collected 
on an Orbitrap Q Exactive Plus mass spectrometer (Thermo 
Fisher Scientific) in a data-dependent mode with one MS 
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precursor scan followed by 15 MS/MS scans as previously 
described [11]. Detailed information on instrument parame-
ters and mass spectra collection is provided in the Additional 
file 1: Supplemental materials and methods (1a). The mass 
spectrometry proteomics data have been deposited to the 
ProteomeXchange Consortium [12] via the PRIDE partner 
repository with the dataset identifier PXD002612.
Protein identification
Protein identification was performed similarly to Zhang 
et  al. [13]. Detailed information can be found in Addi-
tional file 1: Supplemental materials and methods (1b).
Immunohistochemistry of lung cancer LC003 TMA
Preparation of LC003 TMA
A tissue microarray (LC003) was prepared from FFPE 
tissue blocks containing non-malignant and malignant 
(tumor) tissues obtained from 40 patients diagnosed with 
early stage (Stage I and II) NSCLC adenocarcinoma after 
patient consent using an IRB approved protocol (IRB 
293828, UC Davis Cancer Center Biorepository). Three 
0.6  mm (diameter) by 0.4  mm (length) cylindrical cores 
of tumor and adjacent non-malignant (control) lung tis-
sues were collected from each case and placed in the same 
block (Quick-Ray Manual Tissue Microarrayer). One 
TMA section was stained with H&E (hematoxylin and 
eosin) to confirm the presence of tumor and normal lung 
tissue. Clinical data (gender, age, smoking history, diagno-
sis and stage) information was provided after analysis.
Immunohistochemistry of LC003 TMA
Immunohistochemical staining was performed on 4-μm 
FFPE tissue sections from the LC003 TMA for three dif-
ferent protein targets, HYOU1, EPRS and LASP1. Details 
of the IHC procedure are provided in Additional file  1: 
Supplemental materials and methods (1c).
Immunostained slides were scored by a pathologist 
(YZ) blinded to clinicopathologic information. Stain-
ing for HYOU, EPRS and LASP1 was semi-quantified 
assessed using both intensity and percentage of positive 
cells. Staining intensity was graded as 0 =  negative (no 
cells stained); 1 = weak; 2 = moderate; 3 = strong. The 
H score was calculated by multiplying the percentage of 
positive cells demonstrating each density (score 0 to 3) 
and adding the results. The average H score of 3 cores 
in a case was calculated. High expression was defined as 
H score 251–300; medium expression was H score 151–
250; low expression was H score less than 150.
Statistical analysis
Detailed information on statistical analyses are provided 
in Additional file  1: Supplemental Materials and meth-
ods (1d). A conservative approach was used to overview 
data quality metrics in order to identify the most robust 
proteomic measurements for downstream statistical and 
multivariate analyses [11]. A total of 799 high quality pro-
tein measurements (spectral counts) based on absence 
of abundant missing zeros, replicate precision, protein 
sequence coverage and annotation to known genes were 
selected for further statistical and multivariate analyses.
Statistical analyses were conducted on mean normal-
ized count data. Statistical tests were conducted using 
generalized negative binomial mixed effects regression 
with the patients as the random term [14]. Significantly 
altered proteins were identified based on the comparison 
of the full model (Chi squared test) including age + gen-
der + packs + tumor/control to a reduced model exclud-
ing the tumor/normal labels. Model p-values were 
adjusted for multiple hypotheses tested [15].
Orthogonal partial least squares discriminant analysis 
(O-PLS-DA) multivariate models were used to identify 
the top 10% of all protein discriminants between tumor 
and control tissues as previously described [16].
A Gaussian graphical model protein–protein empirical 
network was calculated for O-PLS-DA selected top dis-
criminants (n = 16) as previously described [16].
All subjects were included in the survival analysis with 
the exception of six subjects who did not die of lung can-
cer 23–2262  days from their surgery, and who, before 
their death, never had recurrent lung cancer. Kaplan–
Meier survival curves were generated using Prism v5.0 
(GraphPad Software, Inc). Significance was determined 
using log-rank Mantel-Cox test. Cox proportional hazard 
models were carried out in R statistical software.
LASP1 transcriptomic data
LASP1 transcriptomic data was obtained from the Okayama 
NSCLC study [17] using the Oncomine Database [18]. The 
study set was chosen due its specific focus on early stage 
NSCLC adenocarcinoma and availability of clinicopatholog-
ical variables. Only Stage I (IA/IB) adenocarcinoma subjects 
were considered. Subject characteristics are provided in 
Additional file 1: Table S5. LASP1 values were log2-median 
centered normalized. Cox proportional hazard models were 
used to evaluate the association between LASP1 mRNA 
expression and overall survival.
Results
Paired tissue samples were obtained from 38 patients 
with adenocarcinoma histology (Table  1). The majority 
of subjects were white female former smokers. The aver-
age age was 70 with a mean of 33 packs per year; subjects 
were diagnosed with stage IA or IB adenocarcinoma. Of 
the 38 patients, 14 (36.8%) progressed.
Proteomic profiling was performed on matched malig-
nant and control tissue and yielded a total of 10,712 
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protein groups (see “Methods”). A conservative fil-
ter criteria approach was used to select 799 of the most 
robust proteomic measurements for further statistical 
analyses (Additional file  2: Table S1). Generalized nega-
tive binomial mixed effects regression models were used 
to identify 436 differentially expressed proteins in lung 
adenocarcinoma relative to control tissue, of which 367 
remained significantly different following FDR adjustment 
(Additional file 1: Table S2). O-PLS-DA multivariate clas-
sification modeling was used to select the top 10% multi-
variate discriminants between tumor and control tissues 
(Table 2). Monte Carlo cross-validation and permutation 
testing were used to validate the models predictive per-
formance for classification of cancer vs. control tissues 
(Additional file  1: Table S3). The top 10% discriminants 
between tumor and control tissue consisted of 16 proteins 
with 8 being significantly higher in tumor tissue relative 
Table 1 Patient characteristics
Variable Lung cancer patients
Total sample size, N 38
Gender, N (males/female) 14/24
Age, mean ± SD (min, max) 70 ± 9 (56, 91)
Packs per year, mean ± SD (min, max) 33 ± 25 (0, 100)
Current smoker, N (%) 6 (15.79%)
Stage
 Stage IA, N (%) 21 (55.3%)
 Stage IB, N (%) 17 (44.7%)
Developed lymphovascular invasion, N (%) 6 (15.8%)
Developed pleural invasion, N (%) 13 (34.2%)
Progressed, N (%) 14 (36.84%)
 Local–regional, N 4
 Second primary, N 3
 Distal, N 7
Table 2 Top 10% discriminants of adenocarcinoma
a Values represent covariate adjusted spectral counts
b Ratio of means relative to control
c False discovery rate adjusted mixed effects model p value
d Ratio represents the number of tumor samples which indicated a higher abundance relative to matched control tissue
e Percent (%) represents number of cases were the respective protein was increased in tumor relative to control
f Importance of metabolic change based on O-PLS-DA model loading
Gene ID Gene name Control (mean ± SD)a Tumor (mean ± SD)a Fold changeb p valuec Ratiod Percent (%)e Rankf
SPTB Spectrin, beta, erythrocytic 10.7 ± 9.3 2.82 ± 2.6 0.3 <0.0000 (7/38) 18 1
SLC4A1 Solute carrier family 4 (anion 
exchanger), member 1 
(Diego blood group)
8.75 ± 5.2 3.8 ± 2.7 0.4 <0.0000 (9/38) 24 2
SPTA1 Spectrin, alpha, erythrocytic 1 13.3 ± 12 4.28 ± 3.4 0.3 <0.0000 (8/38) 21 3
ANK1 Ankyrin 1, erythrocytic 6.28 ± 5.7 1.84 ± 1.8 0.3 0.0001 (8/38) 21 4
EPRS Glutamyl-prolyl-tRNA syn-
thetase
1.24 ± 0.87 3.15 ± 1.7 2.5 <0.0000 (30/38) 79 5
HBG1 Hemoglobin, gamma A 16.9 ± 9.7 7.44 ± 6.2 0.4 <0.0000 (9/38) 24 6
HBG2 Hemoglobin, gamma G 17 ± 9.7 7.43 ± 6.2 0.4 <0.0000 (9/38) 24 7
COPG1 Coatomer protein complex, 
subunit gamma 1
1.56 ± 1 2.67 ± 1.4 1.7 0.0036 (29/38) 76 8
HYOU1 Hypoxia up-regulated 1 2.12 ± 1.9 4.74 ± 2.3 2.2 <0.0000 (31/38) 82 9
PTRF Polymerase I and transcript 
release factor
7.35 ± 2.8 3.81 ± 2.8 0.5 0.0001 (4/38) 11 10
PDIA4 Protein disulfide isomerase 
family A, member 4
2.69 ± 2.2 6.23 ± 3.4 2.3 0.0003 (31/38) 82 11
APEX1 APEX nuclease (multifunc-
tional DNA repair enzyme) 1
0.778 ± 0.83 2.05 ± 1.1 2.6 <0.0000 (32/38) 84 12
STOML2 Stomatin (EPB72)-like 2 0.675 ± 0.39 1.38 ± 0.57 2 0.0084 (32/38) 84 13
LRPPRC Leucine-rich pentatricopep-
tide repeat containing
1.31 ± 1.4 3.52 ± 2.5 2.7 0.0001 (29/38) 76 14
NANS N-acetylneuraminic acid 
synthase
0.61 ± 0.55 1.64 ± 1.1 2.7 0.0002 (31/38) 82 15
HBD Hemoglobin, delta 47.3 ± 32 21.7 ± 18 0.5 0.0001 (8/38) 21 16
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to control (Table 2). A Gaussian graphical model network 
was calculated to identify conditionally independent rela-
tionships (partial correlation, pFDR ≤ 0.05) between the 
top discriminatory proteins for adenocarcinoma, the rela-
tionships between which were finally expressed as non-
parametric Spearman’s rank correlations (FDRp  <  0.05) 
(Fig. 1).
NSCLC adenocarcinoma is characterized by alterations 
in DNA repair mechanisms, antioxidant defense capacity, 
altered membrane integrity and metabolism
SPTB was determined to be the single most discrimina-
tory protein of adenocarcinoma displaying a 70% reduc-
tion in tumor tissue relative to control tissue (Table 2). 
The adenocarcinoma-dependent reduction in SPTB was 
also consistently observed in 82% of subjects. Tumor-
associated reductions in SPTB were associated with 
similar reductions in SPTA1 (70%), SLC4A1 (60%), and 
ANK1 (70%) in tumor tissue when compared to control 
tissue (Fig. 1; Table 2). The reduction in SPTA1 was also 
directly correlated with similar reductions in the hemo-
globin subunits HBD, HBG1 and HBG2, which were also 
found to be directly correlated among each other (Fig. 1). 
Reductions in SPTA1 and SPTB were indirectly asso-
ciated with APEX1, which showed a 2.7-fold increase 
in adenocarcinoma compared to non-malignant tissue 
and was consistently elevated in 82% of subjects (Fig. 1; 
Table  2). The increase in APEX1 was correlated with 
similar increases in HYOU1 and NANS, which were 
also increased 2.2- and 2.7-fold in malignant compared 
to non-malignant tissue (Fig.  1; Table  2). HYOU1 and 
NANS were both positively correlated with adenocar-
cinoma-associated increases in EPRS, which was also 
positively associated with LRPPRC and COPG1 (Fig. 1). 
EPRS was repeatedly elevated in adenocarcinoma rela-
tive to control in 79% of cancer subjects, whereas both 
LRPPRC and COPG1 were consistently elevated in 76% 
of subjects (Table 2). Adenocarcinoma-dependent eleva-
tions in LRPPRC were associated with similar increases 
in STOML2 and PDIA4, which exhibited 2- and 2.3-fold 
increases in adenocarcinoma relative to control tissue, 
respectively (Fig. 1; Table 2). NANS, COPG1 and PDIA4 
were all negatively associated with adenocarcinoma-
dependent reductions in PTRF, which was generally 
decreased in adenocarcinoma compared to control tis-
sue (89% of patients).
mRNA expression data from the Okayama et al. study 
on NSCLC adenocarcinoma [17] was used to strengthen 
the adenocarcinoma-associated proteomic perturba-
tions. Only Stage I NSCLC adenocarcinomas were con-
sidered. Consistent with our proteomic data, mRNA 
expression of APEX1, HYOU1, PDIA4, NANS, LRPPRC, 
EPRS and COPG1 were significantly (Mann–Whitney 
U  <  0.05) higher in adenocarcinoma compared to con-
trol whereas mRNA abundance of HBG1, HBG2, HBD, 
and PTRF were significantly (Mann–Whitney U < 0.05) 
lower (Additional file  1: Figure S1). No significant dif-
ferences were observed for SCL4A1, SPTB, SPTA1 and 
ANK1. STOML2 was not detected in the Okayama Lung 
dataset.
Fig. 1 Gaussian graphical model empirical network for O-PLS-DA selected top 10% discriminants between normal and tumor tissues. Edge color 
and width denote the direction and magnitude of partial correlations (pFDR ≤ 0.05). Node color displays the direction of the change in tumor 
relative to non-malignant tissue (green, decrease; red, increase; pFDR ≤ 0.05). Node inset box and whisker plots summarize differences in spectral 
measurements between tumor and non-malignant tissue
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Validation of HYOU1 and EPRS by immunohistochemistry 
of LC003 NSCLC adenocarcinoma TMA
Immunohistochemistry of a tissue microarrays (LC003 
TMA) for NSCLC adenocarcinoma and matched con-
trols (n =  40) was used to validate our proteomic find-
ings. We focused on EPRS and HYOU1 due to both 
proteins being in the top 10% features that distinguish 
malignant from control tissue and due to their positive 
staining based on the Cancer Protein Atlas. All TMA 
results were blindly scored using s manual “H” scoring 
system (“Methods”).
EPRS and HYOU1 immunostaining were elevated 
in adenocarcinoma relative to control tissue (Fig.  2). 
Immunostaining revealed EPRS cytoplasmic expression 
in 36 (90%) cases. Of 36 cases, medium expression was 
observed in 11 (30.5%) cases (Additional file  1: Figure 
S2). Twenty-five (69.5%) adenocarcinoma cases showed 
low expression (Additional file 1: Figure S2). Representa-
tive sections of control tissue and adenocarcinoma are 
provided in Fig. 2b. EPRS exhibited an AUC of 0.841 (CI 
0.788–0.866; p < 0.001) for classifying tissue as malignant. 
HYOU1 was expressed in all 40 (100%) cases of adeno-
carcinoma (Fig.  2d). Representative sections of control 
tissue and adenocarcinoma are provided in Fig. 2e. Mac-
rophages and rare reactive pneumocytes in control tis-
sue demonstrated weak staining (Fig.  2e). The staining 
of HYOU1 in adenocarcinoma cells was localized in the 
cytoplasm (Fig. 2e). HYOU1 staining was high in 14 cases 
(35%), medium in 21 cases (52.5%) and low in 5 cases 
(12.5%) (Additional file  1: Figure S2) and exhibited an 
AUC of 0.952 (CI 0.917–0.976; p < 0.001) for classifying 
tissue as malignant.
Fig. 2 TMA Validation of EPRS and HYOU1. a IHC scores for EPRS in TMA. b Representative IHC sections of EPRS in adenocarcinoma and control. 
c EPRS receiver operating characteristic (ROC) curve and statistical analysis for all 40 cases and controls using results from the LC003 TMA. d IHC 
scores for HYOU1 in TMA. e Representative IHC sections of HYOU1 in adenocarcinoma and control. f Receiver operating characteristic (ROC) curve 
for HYOU1 in TMA
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Association between proteomic signatures and overall 
survival
Lymphovascular invasion (LVI) is a negative prognos-
tic factor for development of distant metastasis and 
long-term survival in NSCLC, particularly in early stage 
lung adenocarcinoma [19, 20]. LVI was significantly 
associated with poor overall survival in our cohort 
(Fig.  3a). We further probed whether our proteomic 
findings would provide prognostic value independ-
ent of LVI as part of the discovery phase. All proteins 
were considered for this analysis. Six individuals of 
the 38 subjects from our cohort were excluded from 
the analysis as their deaths were not due to cancer. We 
identified LASP1 as a negative predictor of overall sur-
vival (Fig.  3b). Multivariate Cox proportional hazard 
models were used to determine hazard ratios between 
Fig. 3 Association between LASP1, lymphovascular infiltration and survival. Kaplan–Meier survival curves are shown for subjects stratified presence 
of lymphovascular infiltration (LVI) (a) or by LASP1 protein abundance cutoff of 2.1 (b). c Multivariate Cox proportional hazard ratios are shown for 
LASP1 as a continuous variable and LASP1 with a cutoff of 2.1 spectral counts. Only LASP1 was a significant independent risk factor for overall sur-
vival when evaluated as a continuous variable but not at optimal x-tile derived cutoff of 2.1 spectral counts when accounting for other co-variants. 
d IHC scores for LASP1 in TMA. e Representative IHC sections of LASP1 in adenocarcinoma and control. f Receiver operating characteristic (ROC) 
Curve for LASP1 in TMA
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LASP1  +  LVI  +  Age  +  Gender and overall survival. 
LASP1 as a continuous variable was determined to be 
an independent prognostic factor for overall survival 
(hazard ratio of 3.66 [CI 1.37–9.78; p  =  0.01)] when 
including LVI + Age + Gender as covariables (Fig. 3c). 
However, only LVI was a significant prognostic factor 
for overall survival when an x-tile [21] derived optimum 
LASP1 cutoff value of 2.1 spectral counts was used (HR 
6.84; CI 1.61–29.10; p = 0.0097) (Fig. 3c). When consid-
ering subjects that died as a consequence of NSCLC ade-
nocarcinoma based on our proteomic findings an AUC 
of 0.755 (CI 0.572–0.889; p  =  0.0107) was determined 
(Additional file 1: Figure S3). Additionally, TMA results 
indicated that most adenocarcinoma cases revealed low 
expression of LASP1 immunostaining (18/23, 78.2%) 
(Fig. 3d; Additional file 1: Figure S3). Representative sec-
tions of control tissue and adenocarcinoma from the 
TMA are provided in Fig.  3e. Overall LASP1 indicated 
moderate classification performance with an AUC of 
0.611 (CI = 0.544–0.675) (Fig. 3f ). Survival information 
was not available for TMA results.
To further evaluate the association between LASP1 
and overall survival we utilized LASP1 mRNA data from 
Okayama et  al. [17] study on NSCLC adenocarcinoma. 
Only stage I NSCLC adenocarcinomas were considered. 
Multivariate Cox proportional hazard models including 
Gender  +  Age  +  Smoking Status  +  LASP1 mRNA as a 
continuous variable indicated that LASP1 mRNA abun-
dance was a significant negative predictor of overall survival 
per unit increase (HR 9.948; CI 8.931–10.965; p  <  0.001) 
(Table 3). Kaplan–Meier survival curves for LASP1 stratified 
by quantiles are shown in Additional file 1: Figure S4. These 
findings coincide with our proteomic findings and highlight 
the potential of LASP1 as a candidate prognostic marker for 
early stage NSCLC adenocarcinoma.
Discussion
In the current study, we evaluated the proteome of 38 
malignant and matched control tissue of stage IA and IB 
lung adenocarcinoma. Differential analysis identified 436 
differentially expressed proteins in adenocarcinoma com-
pared to control tissue, of which 367 remained significant 
following false-discovery rate adjustment. Orthogonal 
partial least squares discriminant analysis identified the 
top 10% proteins that significantly differed between ade-
nocarcinoma and control tissue. A Gaussian graphical 
model network was used to identify conditionally inde-
pendent empirical protein–protein relationships between 
O-PLS-DA selected discriminants for adenocarcinoma. 
Of the 16 distinguishing proteins, 8 were significantly 
elevated in lung adenocarcinoma (COPG1, STOML2, 
HYOU1, PDIA4, EPRS, APEX1, LRPPRC and NANS) 
whereas 8 proteins were significantly decreased in lung 
adenocarcinoma (SPTB, SPTA1, ANK1, SLC4A1, HBG1 
and HBG2). A subsequent sub-analysis was conducted to 
further evaluate the prognostic capacity of using all iden-
tified proteins.
Top discriminatory proteins of adenocarcinoma indicate 
heightened intrinsic defense mechanisms, altered 
metabolism and perturbed membrane integrity
NANS (N-acetylneuraminic acid synthase) exhibited the 
largest increased (2.7-fold) in lung adenocarcinoma rela-
tive to control and was consistently elevated in 82% of the 
subjects. The elevation in NANs suggests increased bio-
synthesis of sialic acid, which is known to be elevated in 
many cancers and may exhibit immune-modulatory and 
anti-apoptotic functions [22]. Elevation in NANS was 
positively correlated with adenocarcinoma-associated 
elevations in APEX1 (apurinicapyrimidinic endonucle-
ase), an important component of base excision repair 
Table 3 Hazard ratios for LASP1 mRNA abundance and overall survival in Okayama Dataset
a Per unit increase
Variable Univariate Multivariate
Hazard ratio 95% CI p value Hazard ratio 95% CI p value
Gender
 Female Reference Reference
 Male 1.333 (0.38–2.286) 0.55 0.953 (–0.35–2.256) 0.94
Age
 ≤61 years of age Reference Reference
 >61 years of age 1.674 (0.708–2.64) 0.3 1.865 (0.889–2.841) 0.21
Smoking
 Never smoker Reference Reference
 Smoker 1.699 (0.746–2.652) 0.28 1.509 (0.21–2.808) 0.53
LASP1a 9.567 (8.571–10.563) <0.001 9.948 (8.931–10.965) <0.001
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(BER) pathway and transcriptional modulator of genes 
that protect against oxidative stress [23]. Over expression 
of APEX1 has been described in NSCLC and other can-
cers [23], while its down-regulation may induce apoptosis 
[24]. The elevation in APEX1 is particularly interesting 
since radiotherapy/chemotherapy induce DNA damage 
and promote production of cytotoxic reactive oxygen 
species (ROS) [25]. An increase in repair machinery and 
anti-oxidant defense systems within a tumor cell could 
interfere with these treatments. APEX1 has been linked 
to chemotherapy/radiotherapy resistance [26].
The elevation in APEX1 was paralleled by an increase 
in HYOU1, a heat shock protein, which has important 
roles in hypoxia and angiogenesis and is linked to tumor 
prognosis [27]. Increased HYOU1 also positively cor-
related with PDIA4, a known modulator of redox sta-
tus, which has been shown to promote drug resistance 
to cisplatin in lung adenocarcinoma [28, 29]. PDIA4 
also directly correlated to LRPPRC. LRPPRC acts as a 
regulator of mitochondrial DNA-encoded mRNAs and 
participates in glucose homeostasis, energy metabo-
lism and nuclear receptor activation [30, 31] and is 
abundantly expressed in NSCLC adenocarcinoma and 
other cancers [30]. Knockdown of LRPPRC promotes 
apoptosis and reduces tumor invasiveness [30]. Eleva-
tion in LRPPR was paralleled by increases in STOML2 
and COPG1. STOML2, a member of the stomatin fam-
ily, is upregulated in numerous cancers and linked to 
tumor aggressiveness [32]. COPG1 is a component of the 
COPI complex, an integral component in lipid homeo-
stasis that promotes lipolysis through the association of 
PNPLA2, a triglyceride lipase, with lipid droplets [33]. 
Lipid metabolism is known to be perturbed in various 
malignancies acting as energy sources, signaling moie-
ties and for biosynthesis of structural membrane lipids 
facilitating increased proliferative potential [34]. Cancer 
cells not only rely on de novo fatty acid synthesis, but also 
take fatty acids from their surrounding microenviron-
ment [34]. We previously reported that malignant cells 
exhibit perturbations in free fatty acid profiles with most 
fatty acids being decreased in tumorous tissue, with the 
exception of arachidonic acid that was elevated in tumor 
compared to non-tumor tissue [16]. Free fatty acids, par-
ticularly arachidonic acid, serve as substrates for genera-
tion of inflammatory mediators. This may also provide a 
basis for the tumor-associated elevation in EPRS, which 
was positively correlated with LRPPRC and COPG1. 
EPRS (glutamyl-prolyl-tRNA synthetase) is a bifunc-
tional enzyme thought to be a gatekeeper of inflamma-
tory gene translation, modulator of angiogenesis and 
regulator of amino-acid stress responses [35]. EPRS is 
also regulated by c-Myc, which is commonly amplified 
in lung adenocarcinoma and modulates tumor metabo-
lism [36, 37]. Collectively, increases in LRPRRC, COPG1, 
EPRS and STOML2 all point towards alterations in 
energetics, metabolism and alterations in inflammatory 
responses that accompany transformation.
Adenocarcinoma-associated reductions in spec-
trins, SPTB and SPTA1, and ankrin (ANK1) all interact 
with each another to regulate cell shape and membrane 
integrity, so paralleled changes likely reflect changes in 
cell adherence, which is a known hallmark of metastatic 
cancer [38]. Alterations in SPTB and ANK1 also indi-
cate changes in rearrangement of transmembrane pro-
teins, including ion channels, which may account for 
the observed positive correlation between SPTB and 
SLC4A1, a membrane bound anion exchange transporter. 
SLC4A1 plays central roles in pH homeostasis and has 
been linked to tumor aggressiveness in numerous cancer 
types [39]. Since most cancer cells exhibit a metabolic 
shift towards acidic-producing pathways, reflective of 
both oncogenic signaling and hypoxia, upregulation of 
pH-regulatory transport proteins may be important [39]. 
An alteration in SLC4A1 represents an attractive target 
for therapeutic intervention and may provide diagnostic 
value.
LASP1 as a potential negative prognostic indicator 
for overall survival
LIM and SH3 domain protein (LASP1) a dynamic protein 
involved in cell structure, physiological processes and cell 
signaling, is significantly expressed in various malignan-
cies and associated with tumor aggressiveness [40] and 
is reported to be an independent prognostic factor in 
patient’s survival for gastric cancer [41] and hepatocellu-
lar carcinoma [42]. We also found that LASP1 was asso-
ciated with poor overall survival in our cohort. When 
considered as a continuous variable, LASP1 indicated a 
HR of 3.66 (CI 1.37–9.78; p 0.01) per unit increase for 
increased risk of death. Notably, adenocarcinoma abun-
dance of LASP1 was only significantly higher relative 
to control tissue in those subjects who died (Additional 
file  1: Table S4). To strengthen the association between 
LASP1 and overall survival, we utilized a second inde-
pendent dataset on LASP1 mRNA expression in NSCLC 
adenocarcinoma [17]. LASP1 mRNA expression was a 
significant negative predictor of overall survival. LASP1 
has been shown to promote invasion and metastasis; 
particularly, LASP1 overexpression in pancreatic ductal 
adenocarcinomas was found to be significantly associ-
ated with lymph node metastasis and poor overall sur-
vival [43]. Therefore, it is plausible that tumor-associated 
elevations in LASP1 may contribute to LVI, which could 
explain why we no longer observed a significant hazard 
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ratio when a LASP1 cutoff of 2.1 was used and instead 
only LVI was found to be a significant predictor of over-
all survival. Collectively, these findings highlight the 
potential of LASP1 as a prognostic indicator for NSCLC 
adenocarcinoma. Further studies in larger cohorts are 
required to fully validate these findings.
One limitation of the current study, and others like it, 
was the lack of assessment of tissue microheterogeneity 
at the sub-biopsy level. We acknowledge that changes 
in specific proteins, such as hemoglobin subunits, may 
reflect contamination from red blood cells. However, 
changes in erythrocyte-associated proteins may equally 
reflect altered tumor angiogenesis [44]. Chen et al. used 
2D-PAGE, MALDI MS to analyze Stage I and III lung 
adenocarcinomas and found proteins that were heavily 
implicated in antioxidant response systems and cellular 
metabolism [45] consistent with our findings. Zhou et al. 
used 2D-DIGE with followed-up by TMA IHC and blood 
studies of TyrRS and MACF-1 [46]. However, Zhou et al. 
evaluated tissues from stage II and III lung adenocarci-
noma and thus might not be directly compared to our 
results for stage IA or IB given the inherent heterogene-
ity that exists among different tumor stages. Kikuchi et al. 
conducted in-depth proteomic profiling on lung adeno-
carcinomas and squamous cell carcinomas and compared 
these against control tissue [47]. Similar to our findings, 
Kikuchi et  al. also found tumor-associated elevations in 
numerous mentioned above proteins including HYOU1, 
NANS and PDIA4 [47].
In conclusion, proteomic changes in early stage 
NSCLC adenocarcinoma tissues are consistent with 
known cancer-dependent alterations in repair machinery, 
redox status, energetics, and inflammation. The current 
study identified candidate markers that may help identify 
at-risk subjects and assist with treatment. This study also 
suggests that LASP1 might serve as a potential negative 
prognostic marker for overall survival. Further studies 
in larger cohorts are warranted to confirm and validate 
these findings.
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